Recursion Pharmaceuticals, Inc.
RXRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,854 | $2,049 | $1,353 | $2,917 |
| - Cash | $594 | $392 | $550 | $285 |
| + Debt | $108 | $51 | $51 | $11 |
| Enterprise Value | $1,368 | $1,709 | $854 | $2,643 |
| Revenue | $59 | $44 | $40 | $10 |
| % Growth | 34.1% | 10.6% | 296.8% | – |
| Gross Profit | $14 | $1 | -$9 | $10 |
| % Margin | 23.1% | 2.9% | -21.7% | 100% |
| EBITDA | -$427 | -$308 | -$228 | -$175 |
| % Margin | -725.2% | -701.1% | -573.7% | -1,751.2% |
| Net Income | -$464 | -$328 | -$239 | -$186 |
| % Margin | -788% | -747.7% | -603.5% | -1,864.8% |
| EPS Diluted | -1.69 | -1.58 | -1.36 | -1.05 |
| % Growth | -7% | -16.2% | -29.5% | – |
| Operating Cash Flow | -$359 | -$288 | -$84 | -$159 |
| Capital Expenditures | -$14 | -$12 | -$37 | -$40 |
| Free Cash Flow | -$373 | -$300 | -$121 | -$198 |